Related Experiment Videos
Inter- and intraindividual differences in oral chlorambucil pharmacokinetics
P Hartvig1, B Simonsson, G Oberg
1Hospital Pharmacy, University Hospital, Uppsala, Sweden.
European Journal of Clinical Pharmacology
|January 1, 1988
Summary
Pharmacokinetics of oral chlorambucil show significant inter- and intraindividual variability in chronic lymphocytic leukemia patients. This oral chemotherapy exhibits rapid elimination, impacting treatment efficacy and dosing strategies.
Area of Science:
- Pharmacology
- Oncology
- Clinical Pharmacy
Background:
- Chronic lymphocytic leukemia (CLL) treatment often involves oral chemotherapy.
- Understanding chlorambucil pharmacokinetics is crucial for optimizing patient outcomes.
- Significant variability in drug absorption and metabolism can affect treatment efficacy.
Purpose of the Study:
- To investigate inter- and intraindividual pharmacokinetic variability of oral chlorambucil.
- To analyze plasma concentrations of chlorambucil and its active metabolite.
- To assess the impact of different doses on drug exposure in CLL patients.
Main Methods:
- Five CLL patients received oral chlorambucil in randomized doses (15, 40, 60, 70 mg).
- Plasma samples were analyzed for chlorambucil and phenyl acetic acid mustard (metabolite).
- Area Under the Curve (AUC) was calculated to determine drug exposure and variability.
Main Results:
- Chlorambucil AUC showed 2- to 4-fold interindividual variation across dose levels.
- The metabolite's AUC was higher, with 2-fold interindividual variation.
- Intraindividual dose-corrected AUC also varied by 2-fold; no dose dependency was observed.
- Rapid elimination was noted for both chlorambucil (t½=1.01h) and metabolite (t½=1.94h).
Conclusions:
- Oral chlorambucil exhibits substantial pharmacokinetic variability in CLL patients.
- This variability may necessitate individualized dosing for optimal therapeutic effect.
- Rapid drug elimination suggests careful monitoring of treatment response is essential.